PFE Pfizer Inc
FY2025 10-K
Pfizer Inc (PFE) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Global pharma innovator generating 65% of revenues from 12 products >$1B each; Eliquis alone = 13% of total revenues in 2025
- • Chantix returned to U.S. market in 2025 after 2021 recall; Oxbryta voluntarily withdrawn globally following negative benefit-risk assessment
Management Discussion & Analysis
- • Revenue $62.2B in 2025, up ~$0.7B (~1%) YoY from $63.6B in 2024; international ops $25.5B (41% of total)
- • IRA Medicare Part D Redesign negatively impacted 2025 revenues by ~$1B; Eliquis alone = 13% of total revenues
Risk Factors
- • IRA Medicare Drug Price Negotiation Program: Eliquis, Ibrance, Xtandi, and Xeljanz selected for Maximum Fair Price; IRA Part D Redesign already hit 2025 revenues ~$1B
- • OBBBA (enacted July 4, 2025) cuts Medicaid/ACA funding; CBO estimates 10M more uninsured, threatening product demand and pricing
Financial SummaryXBRL
Revenue
$62.6B
Net Income
$7.8B
Net Margin
12.4%
ROE
9.0%
Total Assets
$208.2B
EPS (Diluted)
$1.36
Operating Cash Flow
$11.7B
Source: XBRL data from Pfizer Inc FY2025 10-K filing on SEC EDGAR. All figures in USD.
Other Pfizer Inc Annual Reports
Get deeper insights on Pfizer Inc
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.